Last reviewed · How we verify
NCT02983318: DiME
Molecular Imaging of Brain Inflammation in Depressive Disorders
trial in Depressive Disorder, Major in 20 participants. Completed in 31 December 2019.
20 March 2019
Quick facts
| Lead sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 28 August 2017 |
| Primary completion | 20 March 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across Canada |
Conditions studied
- Depressive Disorder, Major — all drugs for Depressive Disorder, Major →
- Positron-Emission Tomography — all drugs for Positron-Emission Tomography →
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Who can join
Adults 19 to 105, any sex, with Depressive Disorder, Major or Positron-Emission Tomography. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In a number of neuropsychiatric disorders such as depression, both brain inflammation and glutamate mediated excitotoxicity (cell death through over-activated stimulation) are suspected to play a key role. It is difficult, if not impossible, to determine the potential destructiveness of the inflammatory response seen in disease states by studying the brain's inflammatory cells (microglia) activity in isolation. The investigators are proposing to develop the means to concurrently study inflammatory response (i.e., microglial activity) and its potentially devastating consequence (i.e., glutamate excitotoxicity) across the entire brain in order to establish the importance of inflammation. In this study the investigators propose a phased clinical study whereby the early-phase involves the development of our capacity to study inflammation-mediated damage to brain cells, followed by a feasibility study in patients with clinical depression that tests whether concurrent inflammation and glutamate excess could be measured in key brain regions associated with a depressed mood state.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Novel Tracers and Radionuclides in PET Imaging.
Mason C, Gimblet GR, Lapi SE, Lewis JS. · · 2021 · cited 10× · PMID 34392925 · DOI 10.1016/j.rcl.2021.05.012
Verify or expand the search:
- PubMed search for NCT02983318
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Depressive Disorder, Major
Currently open trials in the same condition.
- NCT07227454 — A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder · Phase 3 · recruiting
- NCT07258485 — A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major · recruiting
- NCT07059234 — The Motor Activity - Subjective Energy (MASE) Project · NA · recruiting
- NCT06982820 — Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia · NA · recruiting
- NCT05553353 — Dosing rTMS for Depression Post-SCI · NA · recruiting
Other London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials
Trials by the same sponsor.
- NCT07588711 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury · NA · not yet recruiting
- NCT07585292 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Musculoskeletal Pain in Cerebral Palsy · NA · not yet recruiting
- NCT07510906 — Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer · NA · not yet recruiting
- NCT03166072 — Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers · NA · not yet recruiting
- NCT06035809 — Sensory Motor Arousal Regulation Treatment (SMART) Study · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02983318 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Last refreshed: 9 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02983318.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing